Co-host: David, GLP-1 User, Tech Enthusiast

The globally acclaimed weight-loss drug class GLP-1 receptor agonists has seen numerous groundbreaking developments in 2024. With a series of breakthrough clinical trials published this year, GLP-1 drugs have demonstrated therapeutic potential far beyond expectations. Initially developed for diabetes treatment and weight management, these drugs are now being explored for a wide array of conditions, including Alzheimer's disease, cardiovascular disorders, chronic kidney disease, osteoarthritis, and polycystic ovary syndrome. GLP-1 drugs are redefining modern medicine, offering new paradigms of treatment. Notably, these advancements not only target adult populations but also pave new paths for addressing adolescent obesity.

In this episode, Stanford scientist Janice unpacks the latest research findings on GLP-1 drugs from 2024. The clinical trials for GLP-1 drugs continue to expand their indications, unlocking new therapeutic possibilities. These groundbreaking advancements are reshaping the modern medical landscape and heralding a revolutionary shift in health management.

Top 10 Clinical Indications for GLP-1 Drugs:

1. Diabetes

2. Adolescent Weight Management

3. Neurodegenerative Diseases - Alzheimer's

4. Psychiatric Disorders and Mental Health - Depression

5. Obstructive Sleep Apnea

6. Cardiovascular Diseases

7. Chronic Kidney Disease

8. Polycystic Ovary Syndrome

9. Osteoarthritis

10.Liver Diseases - Metabolic Dysfunction-Associated Steatohepatitis (.MASH)

「You Will Hear」

02:30 - What is GLP-1? What are its current indications? What are the available drugs?

05:35 - Many ongoing trials are exploring expanded indications for GLP-1 drugs.

09:02 - Studies confirm no adverse effects of GLP-1 drugs on adolescent growth and development.

11:45 - Can GLP-1 drugs treat Alzheimer's disease?

20:03 - GLP-1 drugs as an effective treatment for diabetic patients with cardiovascular diseases.

25:16 - Promising results for GLP-1 drugs in reducing obesity-related osteoarthritis and joint pain.

28:00 - Effects of GLP-1 drugs on polycystic ovary syndrome, obstructive sleep apnea, and non-alcoholic fatty liver disease.

「Hosts」

Janice holds a Ph.D. in Chemistry from Stanford University and has over 15 years of experience studying and working in the U.S. She is a biotech entrepreneur and founder of N1 Life, a company combining cutting-edge molecular and computational technologies to develop innovative drug delivery systems. With an impressive academic track record, including several publications in top journals, Janice has a passion for exploring science, entrepreneurship, and life. Her global network spans industry leaders and adventurous nomads alike. As the resident host of AirDrop From Above, Janice brings her expertise in science and technology, along with her unique life insights, to thought-provoking discussions with guests from various fields.

「Guests」

David has traveled to over 30 countries across Europe, North America, and Australia, accumulating extensive experience in business development and entrepreneurship. A former trailblazer at Apple, David has opened new markets worldwide and even mastered the art of professional poker. Born into a family of healthcare professionals, he brings a unique perspective on practical nutrition and wellness from outside the medical field. He was also one of the earliest GLP-1 users in China and shares his firsthand experience in this episode.

「Producer」 Shuyi

「Music」 Thank You (Dido)

「Find Us Here」

Xiaoyuzhou｜Ximalaya｜Spotify｜Apple Podcast